Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Folate deficiency modifies the risk of CIN3+ associated with DNA methylation levels: a nested case-control study from the ASCUS-COL trial.

European journal of nutrition·2023
Same author

Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women.

PloS one·2021
Same author

Consistency of the S5 DNA methylation classifier in formalin-fixed biopsies versus corresponding exfoliated cells for the detection of pre-cancerous cervical lesions.

Cancer medicine·2021
Same author

Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2019
Same author

Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases.

Oral oncology·2019
Same author

Associations of human gene EPB41L3 DNA methylation and cervical intraepithelial neoplasia in women living with HIV-1 in Africa.

AIDS (London, England)·2018
Same journal

Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial.

Pharmacogenomics·2026
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Features of a Corporation
01:21

Features of a Corporation

389

Digene Corporation.

Richard Obiso1, Attila Lorincz

  • 1Digene Corporation, 1201 Clopper Road, Gaithersburg, MD 20878, USA. obiso@digene.com

Pharmacogenomics
|December 20, 2003
PubMed
Summary
This summary is machine-generated.

Digene Corporation utilizes proprietary Hybrid Capture technology for molecular diagnostics, focusing on women's cancers and infectious diseases. Their HPV DNA test is a standard for cervical cancer screening, aiming for global adoption.

More Related Videos

Corporation
01:24

Corporation

461
S Corporation
01:17

S Corporation

459

Related Experiment Videos

Last Updated: Jan 20, 2026

Features of a Corporation
01:21

Features of a Corporation

389
Corporation
01:24

Corporation

461
S Corporation
01:17

S Corporation

459

Area of Science:

  • Molecular diagnostics
  • Biotechnology
  • Women's health

Background:

  • Digene Corporation specializes in gene-based testing systems.
  • The company focuses on women's cancers and infectious diseases.
  • Proprietary Hybrid Capture technology is central to their product development.

Purpose of the Study:

  • To develop and market gene-based diagnostic tests.
  • To advance screening, monitoring, and diagnosis of human diseases.
  • To establish the Hybrid Capture HPV DNA Test as the global standard for cervical cancer screening.

Main Methods:

  • Application of Hybrid Capture technology for diagnostic test development.
  • Development of tests for human papillomavirus (HPV), Chlamydia, Gonorrhea, hepatitis B virus, and cytomegalovirus.
  • Ongoing research and development for improved molecular diagnostic assays.

Main Results:

  • Hybrid Capture technology successfully applied to various diagnostic tests.
  • The Hybrid Capture 2 (hc2) HPV DNA test is a standard of care for cervical cancer screening in the US.
  • Focus on improving existing products and developing new ones.

Conclusions:

  • Digene's Hybrid Capture technology is effective for molecular diagnostics.
  • The company aims to expand the use of its HPV DNA test globally.
  • Continued innovation in molecular diagnostics for women's health and infectious diseases is a priority.